Show simple item record

dc.contributor.authorLysaght, Joanneen
dc.contributor.authorRavi, Narayanasamyen
dc.contributor.authorReynolds, Johnen
dc.contributor.authorConroy, Melissaen
dc.date.accessioned2024-05-27T08:38:54Z
dc.date.available2024-05-27T08:38:54Z
dc.date.issued2023en
dc.date.submitted2023en
dc.identifier.citationDavern M, Donlon NE, O'Connell F, Gaughan C, O'Donovan C, Habash M, Sheppard AD, MacLean M, Dunne MR, Moore J, Temperley H, Conroy MJ, Butler C, Bhardwaj A, Ravi N, Donohoe CL, Reynolds JV, Lysaght J., Acidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patients, Cancer Immunology Immunotherapy, 2023en
dc.identifier.otherYen
dc.descriptionPUBLISHEDen
dc.description.abstractTumour acidosis contributes to cancer progression by inhibiting anti-tumour immunity. However, the effect of acidosis on anti-tumour T cell phenotypes in oesophageal adenocarcinoma (OAC) is unknown. Therefore, this study investigated the effect of acidosis on anti-tumour T cell profiles and if immune checkpoint blockade (ICB) could enhance anti-tumour T cell immunity under acidosis. Acidic conditions substantially altered immune checkpoint expression profiles of OAC patient-derived T cells, upregulating TIM-3, LAG-3 and CTLA-4. Severe acidosis (pH 5.5) significantly decreased the percentage of central memory CD4+ T cells, an effect that was attenuated by ICB treatment. ICB increased T cell production of IFN-γ under moderate acidosis (pH 6.6) but not severe acidosis (pH 5.5) and decreased IL-10 production by T cells under severe acidic conditions only. A link between lactate and metastasis was also depicted; patients with nodal metastasis had higher serum lactate levels (p = 0.07) which also positively correlated with circulating levels of pro-angiogenic factor Tie-2. Our findings establish that acidosis-induced upregulation of immune checkpoints on T cells may potentially contribute to immune evasion and disease progression in OAC. However, acidic conditions curtailed ICB efficacy, supporting a rationale for utilizing systemic oral buffers to neutralize tumour acidity to improve ICB efficacy. Study schematic-PBMCs were isolated from OAC patients (A) and expanded ex vivo for 7 days using anti-CD3/28 +IL-2 T cell activation protocol (B) and further cultured for 48 h under increasing acidic conditions in the absence or presence of immune checkpoint blockade (nivolumab, ipilimumab or dual nivolumab + ipilimumab) (C). Immunophenotyping was then carried out to assess immune checkpoint expression profiles and anti-tumour T cell phenotypes (D). Serum lactate was assessed in OAC patients (E-F) and levels were correlated with patient demographics (G) and the levels of circulating immune/pro-angiogenic cytokines that were determined by multiplex ELISA (H). Key Findings-severe acidic conditions upregulated multiple immune checkpoints on T cells (I). Efficacy of ICB was curtailed under severe acidic conditions (J). Circulating lactate levels positively correlated with circulating levels of pro-angiogenic factor tie-2 and higher serum lactate levels were found in patients who had nodal metastasis (K).en
dc.language.isoenen
dc.relation.ispartofseriesCancer Immunology Immunotherapyen
dc.rightsYen
dc.subjectA2aR; Acidosis; Immune checkpoints; Lactate; Oesophageal adenocarcinoma; Tie-2en
dc.titleAcidosis significantly alters immune checkpoint expression profiles of T cells from oesophageal adenocarcinoma patientsen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/jlysaghten
dc.identifier.peoplefinderurlhttp://people.tcd.ie/meconroyen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/reynoljven
dc.identifier.peoplefinderurlhttp://people.tcd.ie/ravinen
dc.identifier.rssinternalid246644en
dc.identifier.doihttps://doi.org/10.1007/s00262-022-03228-yen
dc.rights.ecaccessrightsopenAccess
dc.subject.TCDThemeCanceren
dc.subject.TCDThemeImmunology, Inflammation & Infectionen
dc.subject.TCDTagCANCERen
dc.subject.TCDTagTumour immunology and immunotherapyen
dc.identifier.rssurihttps://doi.org/10.1007/s00262-022-03228-y
dc.identifier.orcid_id0000-0003-3363-3763en
dc.status.accessibleNen
dc.identifier.urihttp://hdl.handle.net/2262/108499


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record